Seleccione idioma:  
RTICC 2013
Programas RTICC
Seguimiento cientifico

Coordinador: Dr. Luis Montuenga Badia
Centro: Centro para la Investigación Médica Aplicada
Dirección postal: Avda. Pío XII, 55, 31008, Pamplona
Email: lmontuenga[arroba]unav.es

Breve CV: Dr. Luis M. Montuenga got his undergraduate degree with Honors in Biology from the University of Navarra (Spain). He also has a Master of Sciences (MSc) in Neuroendocrine Cell Biology from University College London (UK). In 1984 got his Ph.D. in Biology from the University of Navarra (Spain). He spent two years as postgraduate fellow at the Royal Postgraduate Medical School in London and was Visiting Scientist at the National Cancer Institute (NIH) in Bethesda (Maryland) during three years (1995-1998). He is currently Full Professor of Cell Biology at the School of Medicine of the University of Navarra and Senior Researcher and Head of the Oncology Division of the Center for Applied Medical Research (CIMA), University of Navarra. In the past Dr. Montuenga has been the Head of the Histology and Pathology Department of the School of Medicine (1998-2007) and Vicepresident of Research of the University of Navarra (2008-2011). 

Dr. Montuenga has authored more than 120 peer-reviewed publications in Cell Biology and Oncology, has directed 18 doctoral theses and has given numerous conferences and seminars internationally. His research activity is primarily focused on lung cancer. At the Center of Applied Medical Research he co-leads, together with Dr. Ruben Pio, the Laboratory of Lung Cancer Biomarkers. The laboratory of Biomarker’s is focused on the molecular mechanisms associated with the transformation of normal lung epithelial cells into lung tumors. One of its main translational aims is to find molecular markers related to lung carcinogenesis to develop new strategies for lung cancer early detection. Other research interest of the group is to design new molecular targeted therapies that may be useful in the treatment of lung tumors.

He has served as ad hoc reviewer in a variety of national and international research evaluation agencies and has been involved in the peer review process of a large number of journals of his research field.  He is currently Associate Editor of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC).

He is founding member of the European Union Early Lung Cancer (EUELC), member of the prevention Committee of the IASLC, Active member of the American Association for Cancer Research (AACR) and the European Respiratory Society as well as Spanish scientific research societies like the Asociación Española de Investigación en Cáncer (ASEICA) or the Spanish Society for Cell Biology (SEBC).

In the past editions of the RTICC network, Dr. Montuenga has been the Coordinator for Training and Mobility and now serves as Coordinator of the Respiratory Tract Tumors Program.

Work Packages
Ensayos clínicos
Otros resultados
[Autoimmune hemolytic anemia refractory to medical treatment after chlorine dioxide intake in a patient with idiopathic thrombocytopenic purpura].
Sorigué M, Xicoy B, Grifols JR, Ribera JM
Med Clin (Barc)  2015.  7.  332-3.  PMID: 24952664. 

A new prognostic score for AIDS-related lymphomas in the rituximab-era.
Barta SK, Xue X, Wang D, Lee JY, Kaplan LD, Ribera JM, Oriol A, Spina M, Tirelli U, Boue F, Wilson WH, Wyen C, Dunleavy K, Noy A, Sparano JA
Haematologica  2014.  11.  1731-7.  PMID: 25150257. 

Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ, Bower M, Brühlmann J, Novak U, Furrer H, Tanaka PY, Besson C, Montoto S, Cwynarski K, Abramson JS, Dalia S, Bibas M, Connors JM, Furman M, Nguyen ML, Cooley TP, Beltran BE, Collins JA, Vose JM, Xicoy B, Ribera JM, HIV-Associated Hodgkin Lymphoma in the cART Era Study Group
Cancer  2015.  3.  423-31.  PMID: 25251326. 

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Topp MS, Gökbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foà R, Litzow M, Ribera JM, Rambaldi A, Schiller G, Brüggemann M, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM
Lancet Oncol  2015.  1.  57-66.  PMID: 25524800. 

Clinical usefulness of fluorescence in situ hybridization for detection of MLL rearrangements in acute myeloid leukemia.
Ruiz-Xivillé N, Granada I, Campos D, Cisneros A, Grau J, Xandri M, Arnan M, Lloveras N, Escoda L, Font L, Millá F, Ribera JM
Leuk Lymphoma  2015.  1-3.  PMID: 25549805. 

Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma.
Barta SK, Samuel MS, Xue X, Wang D, Lee JY, Mounier N, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Little RF, Dunleavy K, Wilson WH, Wyen C, Remick SC, Kaplan LD, Ratner L, Noy A, Sparano JA
Ann Oncol  2015.  5.  958-66.  PMID: 25632071. 

Flow cytometry for detection of central nervous system disease in acute myeloid leukemia.
Sorigué M, Juncà J, Sancho JM, Morgades M, Esteban D, Navarro JT, Vives S, Feliu E, Ribera JM
Leuk Lymphoma  2015.  7.  2190-2.  PMID: 25641427. 

Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia.
Barba P, Martino R, Martinez-Cuadron D, Olga G, Esquirol A, Gil-Cortés C, Gonzalez J, Fernandez-Avilés F, Valcárcel D, Guardia R, Duarte RF, Hernandez-Rivas JM, Abella E, Montesinos P, Ribera JM
Leuk Lymphoma  2015.  1-7.  PMID: 25686647. 

Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older.
Vives S, Oriol A, Piernas S, Brunet S, Clapés V, Guardia R, Subirà M, Sierra J, Ribera JM, CETLAM Group
Eur J Haematol  2015.  PMID: 25692738. 
Grupos colaboradores: RD12/0036/0029 , RD12/0036/0071

[Central nervous system relapse in diffuse large B cell lymphoma: Risk factors].
Sancho JM, Ribera JM, en representación del Grupo de Trabajo sobre Diagnóstico, Prevención y Tratamiento de la Infiltración del SNC en pacientes con LBDCG
Med Clin (Barc)  2015.  PMID: 25817451. 

Ministerio de Economia y Competitividad
Red Temática Investigación Cooperativa Sanitaria
Rticc 2012
Red Temática Investigación Cooperativa en Cáncer (RTICC)
Centro de Investigación Cáncer - Campus Miguel de Unamuno - 37007 - Salamanca
(+34) 923294803 - sec.rticc[arroba]usal.es
Sobre la RTICC Programas RTICC Ofertas de empleo y Agenda Seguimiento científico
Red Temática de Investigación Cooperativa en Cáncer · © Copyright 2013 · sec.rticc[arrroba]usal.es · diseño web: detrazos